{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:13:28Z","timestamp":1787508808934,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JBMR Plus"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Previous subgroup analyses from the ACTIVE trial in women with postmenopausal osteoporosis (NCT01343004) using three\u2010dimensional (3D)\u2010processing of dual X\u2010ray absorptiometry (DXA) scans indicated greater increases in total hip cortical volumetric bone mineral density (Ct.vBMD) and estimated indices of hip strength following 18\u2009months of abaloparatide (ABL) versus placebo or teriparatide. The current post hoc analyses describe hip 3D\u2010DXA data for ACTIVExtend (NCT01657162), in which 18\u2009months of ABL followed by 24\u2009months of alendronate (ABL\/ALN) increased hip and spine areal BMD (aBMD) and reduced fracture risk versus placebo (PBO) followed by ALN (PBO\/ALN). In an ACTIVExtend subgroup (ABL\/ALN,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u2009204; PBO\/ALN,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u2009202), hip DXA scans retrospectively underwent 3D modeling via 3D\u2010Shaper software. Changes from baseline in cortical and trabecular compartments were calculated for total hip and hip subregions (femoral neck, trochanter, and shaft). Estimated strength indices comprising cross\u2010sectional moment of inertia, section modulus, and buckling ratio were calculated for each hip subregion. Correlations between bone turnover marker levels at the time of alendronate initiation and subsequent BMD gains with alendronate were also investigated within each group. Total hip trabecular and cortical 3D\u2010DXA parameters increased from baseline in both groups (all\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u20090.001), with greater average increases for ABL\/ALN versus PBO\/ALN (trabecular vBMD: 10.87% versus 4.3%; cortical thickness: 2.32% versus 1.14%; Ct.vBMD: 3.41% versus 1.86%; cortical surface BMD: 5.82% versus 3.0%; all\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u20090.001). Strength indices in the ABL\/ALN group improved in all subregions versus baseline (all\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u20090.0001) and versus PBO\/ALN (all\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u20090.02). In the ABL\/ALN group, collagen type I N\u2010terminal propeptide (P1NP) levels at the time of alendronate initiation correlated with subsequent percent changes in all 3D\u2010DXA parameters with 24\u2009months of alendronate therapy. In conclusion, sequential ABL\/ALN or PBO\/ALN treatment improves trabecular and cortical 3D\u2010DXA parameters at the hip, as well as strength indices of hip subregions, with greater increases with ABL\/ALN versus PBO\/ALN. \u00a9 2022 Radius Health, Inc.\n                    <jats:italic>JBMR Plus<\/jats:italic>\n                    published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.\n                  <\/jats:p>","DOI":"10.1002\/jbm4.10612","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T23:08:47Z","timestamp":1644793727000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by\n                    <scp>3D<\/scp>\n                    Modeling of Hip Dual\u2010Energy X\u2010Ray Absorptiometry (\n                    <scp>DXA)<\/scp>"],"prefix":"10.1093","volume":"6","author":[{"given":"Renaud","family":"Winzenrieth","sequence":"first","affiliation":[{"name":"Galgo Medical  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-1368","authenticated-orcid":false,"given":"Paul","family":"Kostenuik","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.  Boston MA USA"},{"name":"University of Michigan School of Dentistry  Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Boxberger","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Wang","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Humbert","sequence":"additional","affiliation":[{"name":"Galgo Medical  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Package insert","author":"TYMLOS","year":"2021"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11136"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081215"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3452"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2021.03.010"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050336"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00163"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.05.012"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.6.2129"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-04819-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(01)00613-5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544060-00001"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.091108"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-019-1494-1"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43465-019-00009-1"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/230949901402200123"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1109\/TMI.2016.2593346"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05806-1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1118\/1.4944501"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2017.05.002"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.06.021"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3051"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2020-0524"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2602"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0560-z"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbm4.10612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbm4.10612","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbm4.10612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T09:57:01Z","timestamp":1710410221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/7479588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/jbm4.10612"],"URL":"https:\/\/doi.org\/10.1002\/jbm4.10612","archive":["Portico"],"relation":{},"ISSN":["2473-4039","2473-4039"],"issn-type":[{"value":"2473-4039","type":"print"},{"value":"2473-4039","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"assertion":[{"value":"2021-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e10612"}}